EIGER BIOPHARMACEUTICALS INC's ticker is EIGR and the CUSIP is 28249U105. A total of 92 filers reported holding EIGER BIOPHARMACEUTICALS INC in Q3 2022. The put-call ratio across all filers is 0.40 and the average weighting 0.4%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2023 | $38,836 | -24.0% | 43,300 | 0.0% | 0.00% | – |
| Q4 2022 | $51,094 | -81.1% | 43,300 | +20.3% | 0.00% | – |
| Q3 2022 | $271,000 | +29.7% | 36,000 | +8.4% | 0.00% | – |
| Q2 2022 | $209,000 | -14.3% | 33,200 | +12.9% | 0.00% | – |
| Q1 2022 | $244,000 | +59.5% | 29,400 | 0.0% | 0.00% | – |
| Q4 2021 | $153,000 | -26.8% | 29,400 | -6.1% | 0.00% | – |
| Q3 2021 | $209,000 | -21.7% | 31,300 | 0.0% | 0.00% | – |
| Q2 2021 | $267,000 | +0.4% | 31,300 | +4.3% | 0.00% | – |
| Q1 2021 | $266,000 | -27.9% | 30,000 | 0.0% | 0.00% | – |
| Q4 2020 | $369,000 | +51.2% | 30,000 | 0.0% | 0.00% | – |
| Q3 2020 | $244,000 | -15.3% | 30,000 | 0.0% | 0.00% | – |
| Q2 2020 | $288,000 | +119.8% | 30,000 | +55.4% | 0.00% | – |
| Q1 2020 | $131,000 | -14.4% | 19,300 | +87.4% | 0.00% | – |
| Q4 2019 | $153,000 | +44.3% | 10,300 | 0.0% | 0.00% | – |
| Q3 2019 | $106,000 | – | 10,300 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Vivo Capital, LLC | 1,787,091 | $20,462,000 | 6.02% |
| INTERWEST VENTURE MANAGEMENT CO | 1,599,592 | $18,315,000 | 3.89% |
| NEXTHERA CAPITAL LP | 263,600 | $3,018,000 | 1.54% |
| SPHERA FUNDS MANAGEMENT LTD. | 385,301 | $4,412,000 | 0.86% |
| RA Capital Management | 354,200 | $4,056,000 | 0.50% |
| DAFNA Capital Management LLC | 35,977 | $412,000 | 0.35% |
| Boxer Capital, LLC | 138,331 | $1,584,000 | 0.35% |
| SABBY MANAGEMENT, LLC | 238,907 | $2,735,000 | 0.15% |
| Monashee Investment Management LLC | 31,500 | $361,000 | 0.14% |
| Lombard Odier Asset Management (USA) Corp | 100,000 | $1,145,000 | 0.11% |